Medical Lipid-Regulating Therapy
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 64 (11) , 1181-1196
- https://doi.org/10.2165/00003495-200464110-00003
Abstract
Coronary heart disease (CHD) is a major cause of morbidity and mortality worldwide. Elevated low density lipoprotein-cholesterol (LDL-C) and reduced high density lipoprotein-cholesterol (HDL-C)...Keywords
This publication has 102 references indexed in Scilit:
- Inflammation in atherosclerosisNature, 2002
- Effects of HMG-CoA Reductase Inhibitors on Skeletal MuscleDrug Safety, 2002
- Metabolic and Additional Vascular Effects of ThiazolidinedionesDrugs, 2002
- Novel approaches to lipid lowering: what is on the horizon?The American Journal of Cardiology, 2001
- Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.The American Journal of Cardiology, 2001
- Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management∗∗This article represents one side of a debate on the role of lipid subfractions in cardiovascular risk management; the opposing argument can be found in the accompanying article by Terje R. Pedersen, MD, PhD.The American Journal of Cardiology, 2001
- Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agentExpert Opinion on Investigational Drugs, 2000
- Diabetic dyslipidemiaThe American Journal of Cardiology, 1998
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993